estimation of the efficacy and adverse effect of daflon when it is added to the conventional treatments in patients with acute hemorrhoids
Phase 2
- Conditions
- Acute Hemorrhoidal disease.Hemorrhoids and perianal venous thrombosis
- Registration Number
- IRCT20141201020178N9
- Lead Sponsor
- Iran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
age more than 18 years
acute hemorrhoid crisis(anal pain and anal bleeding)
Exclusion Criteria
Grade I and IV of hemorrhoid
previous history of surgery related to the anorectal or hemorrhoid disease
lactation
Patients with the history of other chronic systemic diseases, such as heart, kidney, or liver disease, hypertension, seizure
pregnancy
cancer history
medications such as anti-depressant and flavonoid drugs
non-cooperative
sleep disorders
allergy to daflon
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pain score. Timepoint: Before and two weeks after starting treatment. Method of measurement: VAS.;Bleeding. Timepoint: Before and two weeks after starting treatment. Method of measurement: No bleeding / with every defication / daily / weekly / monthly.;SF-12V1 Health Survey Questionnaire. Timepoint: before and 2 weeks after the starting the treatment. Method of measurement: SF-12V1 questionnaire.
- Secondary Outcome Measures
Name Time Method Patient compliance rate. Timepoint: two weeks after starting treatment. Method of measurement: Data gathering sheet.;Adverse effect rate. Timepoint: 2 weeks after the beginning of the treatment. Method of measurement: patients data gathering sheets.